Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxazosin - Pfizer

Drug Profile

Doxazosin - Pfizer

Alternative Names: Alfadil; Cardenalin; Cardular; Cardura; Cardura XL; Carduran; Dedralen; Diblocin; Doxaben; Doxazosin mesylate; Normothen; Supressin; Tensiobas; UK 33274; UK 3327427; Zoflux

Latest Information Update: 14 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Almirall S.A.; AstraZeneca; Fisons; Libbs Farmaceutica; Lifepharma; Pfizer; Purepac Pharmaceutical; Teva Pharmaceutical Industries; Viatris Inc
  • Class Antihypertensives; Quinazolines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia; Hypertension

Most Recent Events

  • 25 Feb 2005 The US FDA has given final marketing approval for a sustained-release formulation of doxazosin in benign prostatic hyperplasia
  • 23 Nov 2004 A Pharmacoeconomic study has been added to the Men's Health therapeutic trials section
  • 02 Sep 2004 Health Canada has approved the combination treatment of finasteride and doxazosin in reducing the risk of symptomatic progress of benign prostatic hyperplasia
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top